This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Apr 11;307(14):1483-4; author reply 1484-5.

doi: 10.1001/jama.2012.445.

CYP2C19 genotype and cardiovascular events

Gerasimos Siasos, Dimitris Tousoulis, Christodoulos Stefanadis

PMID: 22496257
DOI: 10.1001/jama.2012.445

Comment

CYP2C19 genotype and cardiovascular events

Gerasimos Siasos et al. JAMA. 2012.

. 2012 Apr 11;307(14):1483-4; author reply 1484-5.

doi: 10.1001/jama.2012.445.

Authors

Gerasimos Siasos, Dimitris Tousoulis, Christodoulos Stefanadis

PMID: 22496257
DOI: 10.1001/jama.2012.445

No abstract available

PubMed Disclaimer

Comment on

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. Holmes MV, et al. JAMA. 2011 Dec 28;306(24):2704-14. doi: 10.1001/jama.2011.1880. JAMA. 2011. PMID: 22203539

Similar articles

CYP2C19 genotype and cardiovascular events.
Mega JL, Topol EJ, Sabatine MS. Mega JL, et al. JAMA. 2012 Apr 11;307(14):1482-3; author reply 1484-5. doi: 10.1001/jama.2012.444. JAMA. 2012. PMID: 22496256 No abstract available.
CYP2C19 genotype and cardiovascular events.
Shuldiner AR, Vesely MR, Fisch A. Shuldiner AR, et al. JAMA. 2012 Apr 11;307(14):1482; author reply 1484-5. doi: 10.1001/jama.2012.443. JAMA. 2012. PMID: 22496255 No abstract available.
Pharmacogenomics and clopidogrel: irrational exuberance?
Nissen SE. Nissen SE. JAMA. 2011 Dec 28;306(24):2727-8. doi: 10.1001/jama.2011.1865. JAMA. 2011. PMID: 22203545 No abstract available.
Proton pump inhibitors and clopidogrel.
Gaglia MA Jr, Waksman R. Gaglia MA Jr, et al. Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Epub 2010 Mar 25. Cardiovasc Ther. 2010. PMID: 20345494 Review.
The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ, Tantry US, Gurbel PA. Price MJ, et al. Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Rev Cardiovasc Med. 2011. PMID: 21546883 Review.

See all similar articles

Cited by

Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?
Perry CG, Shuldiner AR. Perry CG, et al. J Hum Genet. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Epub 2013 May 23. J Hum Genet. 2013. PMID: 23697979 Free PMC article. Review.
Pharmacogenomics of anti-platelet and anti-coagulation therapy.
Fisch AS, Perry CG, Stephens SH, Horenstein RB, Shuldiner AR. Fisch AS, et al. Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3. Curr Cardiol Rep. 2013. PMID: 23797323 Free PMC article. Review.
Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y, Lv HH, Liu X, Dong Q, Yang XL, Li SX, Wu S, Jiang JM, Luo Z, Zhu DS, Zhang Y, Zheng Y, Guan YT, Xu JF. Han Y, et al. CNS Neurosci Ther. 2015 Sep;21(9):692-7. doi: 10.1111/cns.12426. Epub 2015 Jul 15. CNS Neurosci Ther. 2015. PMID: 26177117 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information